DBV Technologies (DBVT) - Total Liabilities
Based on the latest financial reports, DBV Technologies (DBVT) has total liabilities worth $62.80 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore DBVT strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
DBV Technologies - Total Liabilities Trend (2011–2025)
This chart illustrates how DBV Technologies's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see DBV Technologies total assets.
DBV Technologies Competitors by Total Liabilities
The table below lists competitors of DBV Technologies ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Canadian Solar Inc
NASDAQ:CSIQ
|
USA | $10.80 Billion |
|
Chenguang Biotech Group
SHE:300138
|
China | CN¥4.57 Billion |
|
China Union Holdings Ltd
SHE:000036
|
China | CN¥1.69 Billion |
|
Apogee Enterprises Inc
NASDAQ:APOG
|
USA | $589.44 Million |
|
Shandong Keyuan Pharmaceutical Co. Ltd. A
SHE:301281
|
China | CN¥222.24 Million |
|
Groupon Inc
NASDAQ:GRPN
|
USA | $671.75 Million |
|
Guangdong Meiyan Jixiang Hydropower Co Ltd
SHG:600868
|
China | CN¥916.96 Million |
|
Zhejiang Zhongcheng Packing Material Co Ltd
SHE:002522
|
China | CN¥1.26 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down DBV Technologies's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See DBV Technologies net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.72 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how DBV Technologies's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for DBV Technologies (2011–2025)
The table below shows the annual total liabilities of DBV Technologies from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $64.95 Million | +69.71% |
| 2024-12-31 | $38.27 Million | -10.58% |
| 2023-12-31 | $42.80 Million | -17.80% |
| 2022-12-31 | $52.06 Million | +10.09% |
| 2021-12-31 | $47.29 Million | -29.15% |
| 2020-12-31 | $66.75 Million | -15.00% |
| 2019-12-31 | $78.54 Million | +13.86% |
| 2018-12-31 | $68.98 Million | +2.33% |
| 2017-12-31 | $67.40 Million | +36.84% |
| 2016-12-31 | $49.26 Million | +94.72% |
| 2015-12-31 | $25.30 Million | +60.73% |
| 2014-12-31 | $15.74 Million | +46.90% |
| 2013-12-31 | $10.71 Million | +65.15% |
| 2012-12-31 | $6.49 Million | -4.40% |
| 2011-12-31 | $6.79 Million | -- |
About DBV Technologies
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobu… Read more